Scholarlink

<p>Central nervous system (CNS) relapse in children with acute lymphoblastic leukemia (ALL) remains an obstacle for long-term survival. Though chimeric antigen receptor T-cells (CAR-T) or hematopoietic stem cells transplant (HSCT) therapy was successfully developed, failure occasionally occurs. In this study, a child with <i>TCF3-PBX1</i> B-ALL who relapsed a second time after CAR-T therapy followed by allo-HSCT was treated with blinatumomab therapy, bone marrow minimal residual disease negativity was confirmed with two weeks’ blinatumomab infusion. Subsequently, parenchymal infiltration improvement was achieved with additional 14&#xa0;days’ blinatumomab-included targeted therapy. These results suggest that blinatumomab-included therapy is a potential treatment option for central nervous system B-ALL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blinatumomab in the treatment of relapsed central nervous system ALL

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Shufang Xue,
  • Gaoyuan Sun,
  • Ruoyao Huang,
  • Han Lin,
  • Shan Liu,
  • Lu Chen,
  • Ying Huang,
  • Chengyi Wang,
  • Yongzhi Zheng,
  • Hui Zhang

摘要

Central nervous system (CNS) relapse in children with acute lymphoblastic leukemia (ALL) remains an obstacle for long-term survival. Though chimeric antigen receptor T-cells (CAR-T) or hematopoietic stem cells transplant (HSCT) therapy was successfully developed, failure occasionally occurs. In this study, a child with TCF3-PBX1 B-ALL who relapsed a second time after CAR-T therapy followed by allo-HSCT was treated with blinatumomab therapy, bone marrow minimal residual disease negativity was confirmed with two weeks’ blinatumomab infusion. Subsequently, parenchymal infiltration improvement was achieved with additional 14 days’ blinatumomab-included targeted therapy. These results suggest that blinatumomab-included therapy is a potential treatment option for central nervous system B-ALL.